Sonic Healthcare Limited (ASX:SHL) entered into an agreement to acquire Diagnosticum Gmbh for ?190 million on April 3, 2023. The purchase price of ?190 million (cash and debt free) will be funded in Euro from Sonic?s existing cash and debt facilities, with the majority of the purchase price being tax deductible in Germany over 15 years as goodwill amortisation. The transaction is immediately earnings per share (EPS) accretive and the return on invested capital (ROIC) will exceed Sonic?s cost of capital. EPS and ROIC accretion will increase as significant synergies in multiple areas of infrastructure and operations (including procurement) are achieved. The transaction is subject to customary closing conditions, including medical regulatory approvals and is expected to occur before the end of the 2023 calendar year. Kai-Steffen Scholz, Hendrik Bockenheimer, Christoph Wilken and Jan Bonhage of Hengeler Mueller acted as legal advisor to Sonic Healthcare on the acquisition of Diagnosticum.

Sonic Healthcare Limited (ASX:SHL) completed the acquisition of Diagnosticum Gmbh on October 2, 2023. Diagnosticum has reported annual revenue ?65 million.